

Special Issue

Advances in Urogenital Pathology

Message from the Guest Editors

The urogenital system, from the kidney to the penis, involves what is likely the widest spectrum of inflammatory, infectious, reactive, and neoplastic entities ever collected along the human body. Kidney, urinary tract, and prostate tumors are neoplasms frequently seen in daily practice, and their clinical management includes several of the most advanced examples of personalized medicine. Actually, new developments in therapies focusing on antiangiogenic, immune checkpoint blockage, and hormonal resistance are current hot topics in modern oncology. On the other hand, the non-neoplastic pathology in this field is frequent and varied, from malformations to reactive-inflammatory conditions and post-surgical complications, in which the latest technological developments deserve attention. This Special Issue intends to serve as a multidisciplinary forum where urologists, medical oncologists and radiotherapists, as well as nuclear medicine specialists, pathologists, radiologists and other specialists, can meet to improve patient care.

Guest Editors

Dr. José I. López

Biobizkaia Health Research Institute, 48903 Barakaldo, Spain

Dr. Claudia Manini

Department of Pathology, San Giovanni Bosco Hospital, 10154 Turin, Italy

Deadline for manuscript submissions

closed (15 April 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/77871

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).